STRATA Skin Sciences to Report Second Quarter 2021 Financial Results on August 16, 2021
STRATA Skin Sciences (NASDAQ: SSKN) plans to announce its Q2 2021 financial results on August 16, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. STRATA focuses on innovative dermatology technologies, including the XTRAC® excimer laser for treating conditions like psoriasis and vitiligo, affecting over 31 million patients in the U.S. DTC advertising and in-house support teams help drive patient volume for its partner clinics.
- Focus on innovative dermatology technologies.
- Opportunities in a large patient market of over 31 million.
- None.
HORSHAM, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its second quarter 2021 financial results after the market closes on Monday, August 16, 2021. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.
The link to the webcast will be available on the STRATA Skin Sciences website at www.strataskinsciences.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 300-8521 (US/Canada) or (412) 317-6026 (International) and use the conference ID 10159329.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
Investor Contact
Leigh Salvo
(415) 937-5404
ir@strataskin.com
FAQ
When will STRATA Skin Sciences release its Q2 2021 financial results?
What time is the STRATA Skin Sciences conference call?
How can I listen to the STRATA Skin Sciences conference call?